Drug intelligence / Profile preview

BGB-B3227

Development stage: Unknown
Lead developer: BeiGene
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

BGB-B3227 is a bispecific antibody targeting MUC1 and CD16A, developed by BeiGene for the treatment of solid tumors, including lung, gastrointestinal, and breast cancers. It is designed to engage both tumor-associated MUC1 and immune cell CD16A to promote antibody-dependent cellular cytotoxicity (ADCC) and stimulate T lymphocyte activity against cancer cells. The drug is currently in phase 1 clinical trials as both monotherapy and in combination with tislelizumab for advanced or metastatic solid tumors.

Other names: BGB B3227

Targets

FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)MUC1 (Mucin-1 Antigen)

Beyond the preview

Go deeper on BGB-B3227.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BGB-B3227.

Explore the full profile